Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA
NCT03119701 · Faron Pharmaceuticals Ltd · PHASE2 · terminated · last registry update 2021-01-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “IDMC recommendation. Unexpectedly high use of concomitant corticosteroid treatment.” | – | Registry record, Faron Pharmaceuticals Ltd |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IFNAR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-30Phase 3 first posted: AstraZeneca, Anifrolumab + Placebo (NCT05138133)
- 2021-11-24Results posted on the registry: AstraZeneca, Anifrolumab + Placebo (NCT02547922)
- 2021-11-22Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Interferon beta-1a + Remdesivir (NCT04492475)
- 2021-11-09Also stopped (withdrawn): Teva Branded Pharmaceutical Products R&D, Inc., Laquinimod + Avonex® (NCT01975298)
- 2021-11-01Also stopped (withdrawn): National Institute of Allergy and Infectious Diseases (NIAID), Adefovir dipivoxil + Peginterferon-alfa-2A (NCT00051077)
- 2021-10-06Results posted on the registry: University of Michigan Rogel Cancer Center, peg-IFN-α + Tacrolimus (NCT02328755)
- 2021-08-05Results posted on the registry: EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032158)
- 2021-08-05Also stopped (terminated): EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032158)
- 2021-08-05Results posted on the registry: EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032171)
- 2021-08-05Also stopped (terminated): EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032171)
- 2021-06-18Phase 3 first posted: AstraZeneca, Anifrolumab + placebo (NCT04931563)
- 2021-05-18Results posted on the registry: Johns Hopkins Bloomberg School of Public Health, Sofosbuvir + Daclatasvir (NCT03480932)
- 2021-05-07Phase 3 first posted: AstraZeneca, Medi-546 + Placebo (NCT04877691)
- 2021-04-15Results posted on the registry: Johns Hopkins Bloomberg School of Public Health, Sofosbuvir + Pegylated Interferon alfa-2a (NCT02541409)
- 2021-03-23Results posted on the registry: Ascletis Pharmaceuticals Co., Ltd., Danoprevir + Ritonavir (NCT03020082)
- 2021-03-09Phase 3 first posted: Novartis Pharmaceuticals, Ofatumumab + First line DMT (NCT04788615)
- 2021-02-25Results posted on the registry: Hepatera Ltd., Myrcludex B + PEG IFN alfa-2a (NCT02888106)
- 2021-02-11Results posted on the registry: Celgene, Ozanimod + Ozanimod placebo (NCT02047734)
- 2021-01-05Also stopped (withdrawn): University at Buffalo, repository corticotropin injection + Saline (NCT00986960)
- 2020-12-07Phase 3 first posted: PharmaEssentia Japan K.K., P1101 (Ropeginterferon alfa-2b) (NCT04655092)
- 2020-12-01Phase 3 first posted: The University of The West Indies, Remdesivir + Acalabrutinib (NCT04647669)
- 2020-11-25Results posted on the registry: Celgene, Ozanimod + Interferon beta-1a (NCT02294058)
- 2020-09-30Also stopped (terminated): Vertex Pharmaceuticals Incorporated, telaprevir + VX-222 (NCT01080222)
- 2020-09-24Also stopped (terminated): M.D. Anderson Cancer Center, Pegylated Interferon Alfa 2a + Ribavirin (NCT01821963)
- 2020-09-17Phase 3 first posted: Pontificia Universidad Catolica de Chile, Peginterferon beta-1a (NCT04552379)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision